Skip to content

Carlisle Companies

US · CSL #1260 by market cap Listed 1970
378.85 -9.06 -2.34%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Citi Maintains CSL LTD(CMXHF.US) With Hold Rating, Raises Target Price to $125.61
    Market Newswire · 2026/10/20
  • Baird Maintains Carlisle Companies(CSL.US) With Buy Rating, Raises Target Price to $410
    Market Newswire · 2026/10/29
  • Company notice
    CSL Ltd: U.S. Section 232 Tariffs on Pharmaceuticals
    ASX · 2026/4/7
  • Rating change
    Morgan Stanley Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $140.31
    Market Newswire · 2026/11/4
  • Rating change
    Morgan Stanley Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $140.62
    Market Newswire · 2026/10/23
  • Company notice
    Cara Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Vifor (International) Ltd.(13.5%),CSL Limited(13.5%)
    SEC · 2024/10/31
  • Rating change
    Morgans Downgrades CSL LTD(CMXHF.US) to Hold Rating, Raises Target Price to $145.48
    Market Newswire · 2026/11/5
  • Rating change
    UBS Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $157.85
    Market Newswire · 2026/11/4
  • Rating change
    Morgan Stanley Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $139.57
    Market Newswire · 2026/10/19
  • Oppenheimer Maintains Carlisle Companies(CSL.US) With Buy Rating, Maintains Target Price $425
    Market Newswire · 2026/10/21
  • Company notice
    CSL Ltd: Update on U.S. Plasma Collection Network
    ASX · 2026/10/8
  • Rating change
    CSL Price Target Raised 24% to A$225.00/Share by UBS
    Dow Jones · 2026/10/30
  • Oppenheimer Maintains Carlisle Companies(CSL.US) With Buy Rating, Raises Target Price to $430
    Market Newswire · 2026/10/30
  • Evans and Partners Downgrades CSL to Neutral, Adjusts Price Target to AU$197.24
    MT Newswires · 2026/11/17
  • Rating change
    UBS Maintains CSL LTD(CMXHF.US) With Buy Rating, Raises Target Price to $158.38
    Market Newswire · 2026/10/30
  • Company notice
    CSL Ltd: Agreements with U.S. on Drug Prices and Manufacturing
    ASX · 2026/9/1
  • Goldman Sachs Maintains Carlisle Companies(CSL.US) With Buy Rating, Raises Target Price to $480
    Market Newswire · 2026/10/29
  • Company notice
    CSL Ltd: CSL prices US$1.5 billion in Corporate Bonds
    ASX · 2026/10/7
  • Rating change
    CSL Price Target Raised 12% to A$210.00/Share by Morgans
    Dow Jones · 2026/11/5
  • Rating change
    CSL Price Target Raised 10% to A$178.00/Share by Jefferies
    Dow Jones · 2026/10/30
  • Rating change
    Baird Maintains Carlisle Companies(CSL.US) With Buy Rating, Cuts Target Price to $402
    Market Newswire · 2026/10/13
  • Rating change
    D.A. Davidson Maintains Carlisle Companies(CSL.US) With Hold Rating, Raises Target Price to $410
    Market Newswire · 2026/8/25
  • Rating change
    Goldman Sachs Maintains Carlisle Companies(CSL.US) With Buy Rating, Announces Target Price $464
    Market Newswire · 2026/10/12
  • Rating change
    CSL Raised to Accumulate From Hold by Ord Minnett CSL.AU
    Dow Jones · 2026/9/16
  • Rating change
    RBC Capital Upgrades CSL LTD(CMXHF.US) to Buy Rating, Raises Target Price to $152.48
    Market Newswire · 2026/9/16

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Carlisle Companies discussion 0 comments

Add a comment